Aberdeen Group plc Sells 5,133 Shares of Jazz Pharmaceuticals PLC $JAZZ

Aberdeen Group plc decreased its stake in Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) by 7.8% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 60,337 shares of the specialty pharmaceutical company’s stock after selling 5,133 shares during the period. Aberdeen Group plc owned 0.10% of Jazz Pharmaceuticals worth $10,257,000 at the end of the most recent quarter.

Several other hedge funds also recently modified their holdings of JAZZ. Empirical Financial Services LLC d.b.a. Empirical Wealth Management raised its position in Jazz Pharmaceuticals by 89.3% during the fourth quarter. Empirical Financial Services LLC d.b.a. Empirical Wealth Management now owns 4,532 shares of the specialty pharmaceutical company’s stock worth $770,000 after acquiring an additional 2,138 shares in the last quarter. Allspring Global Investments Holdings LLC raised its position in Jazz Pharmaceuticals by 10.6% during the fourth quarter. Allspring Global Investments Holdings LLC now owns 15,268 shares of the specialty pharmaceutical company’s stock worth $2,644,000 after acquiring an additional 1,469 shares in the last quarter. Hennion & Walsh Asset Management Inc. raised its position in Jazz Pharmaceuticals by 25.5% during the fourth quarter. Hennion & Walsh Asset Management Inc. now owns 47,535 shares of the specialty pharmaceutical company’s stock worth $8,081,000 after acquiring an additional 9,657 shares in the last quarter. Exchange Traded Concepts LLC bought a new stake in Jazz Pharmaceuticals during the fourth quarter worth $193,000. Finally, Fort Washington Investment Advisors Inc. OH bought a new stake in Jazz Pharmaceuticals during the fourth quarter worth $204,000. Institutional investors own 89.14% of the company’s stock.

Analyst Upgrades and Downgrades

JAZZ has been the topic of several analyst reports. Piper Sandler upped their price target on shares of Jazz Pharmaceuticals from $219.00 to $232.00 and gave the stock an “overweight” rating in a research report on Thursday, March 19th. Royal Bank Of Canada lifted their target price on Jazz Pharmaceuticals from $191.00 to $195.00 and gave the stock an “outperform” rating in a research note on Wednesday, February 25th. Barclays reiterated an “overweight” rating and set a $224.00 target price on shares of Jazz Pharmaceuticals in a research note on Monday, March 9th. Needham & Company LLC lifted their target price on Jazz Pharmaceuticals from $210.00 to $235.00 and gave the stock a “buy” rating in a research note on Monday, January 12th. Finally, Morgan Stanley lifted their target price on Jazz Pharmaceuticals from $225.00 to $226.00 and gave the stock an “overweight” rating in a research note on Wednesday, February 25th. One equities research analyst has rated the stock with a Strong Buy rating, twelve have issued a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $215.38.

Insider Buying and Selling

In other news, Director Norbert G. Riedel sold 3,415 shares of the business’s stock in a transaction dated Friday, February 27th. The shares were sold at an average price of $192.00, for a total value of $655,680.00. Following the completion of the sale, the director owned 7,024 shares of the company’s stock, valued at approximately $1,348,608. The trade was a 32.71% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, Director Bruce C. Cozadd sold 6,000 shares of the business’s stock in a transaction dated Wednesday, April 1st. The shares were sold at an average price of $190.50, for a total transaction of $1,143,000.00. Following the completion of the sale, the director directly owned 384,682 shares of the company’s stock, valued at approximately $73,281,921. The trade was a 1.54% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 74,015 shares of company stock valued at $14,180,486 in the last 90 days. 4.30% of the stock is currently owned by corporate insiders.

Jazz Pharmaceuticals Stock Up 2.2%

Jazz Pharmaceuticals stock opened at $190.94 on Wednesday. The stock has a market cap of $11.75 billion, a P/E ratio of -31.98, a P/E/G ratio of 0.33 and a beta of 0.23. The company has a quick ratio of 1.67, a current ratio of 1.86 and a debt-to-equity ratio of 1.00. Jazz Pharmaceuticals PLC has a twelve month low of $95.49 and a twelve month high of $198.00. The company’s 50-day moving average price is $178.27 and its two-hundred day moving average price is $163.22.

Jazz Pharmaceuticals (NASDAQ:JAZZ) last released its quarterly earnings results on Wednesday, February 25th. The specialty pharmaceutical company reported $6.64 earnings per share for the quarter, beating the consensus estimate of $6.49 by $0.15. The firm had revenue of $1.20 billion for the quarter, compared to analysts’ expectations of $1.17 billion. Jazz Pharmaceuticals had a negative net margin of 8.35% and a positive return on equity of 6.87%. The business’s revenue was up 8.1% on a year-over-year basis. During the same period in the prior year, the firm earned $6.51 EPS. As a group, analysts expect that Jazz Pharmaceuticals PLC will post 16.96 EPS for the current year.

Jazz Pharmaceuticals Profile

Jazz Pharmaceuticals plc is a global biopharmaceutical company focused on developing and commercializing therapies in neuroscience and oncology. The company’s research and development efforts target unmet medical needs in sleep disorders, hematologic malignancies, rare neurological conditions and solid tumors. Jazz’s product portfolio includes therapies for narcolepsy, hepatic veno-occlusive disease, acute myeloid leukemia and other serious disorders.

Flagship products from Jazz Pharmaceuticals include Xyrem® (sodium oxybate) and Xywav® (calcium, magnesium, potassium, and sodium oxybates) for the treatment of cataplexy and excessive daytime sleepiness in patients with narcolepsy.